Choices aplenty: antifungal prophylaxis in hematopoietic stem cell transplant recipients

Area of Science:

• Mycology
• Hematology
• Infectious Diseases

Background:

• Invasive fungal infections (IFIs) affect 10-25% of hematopoietic stem cell transplantation (HSCT) recipients, with high fatality rates (70-90%).
• Candida and Aspergillus species are the most frequent pathogens causing IFIs in this vulnerable population.
• Current fluconazole prophylaxis is limited, lacking efficacy against invasive aspergillosis and other molds.

Purpose of the Study:

• To review advancements in antifungal therapies and diagnostics for IFIs in HSCT recipients.
• To explore the potential shift from prophylaxis to pre-emptive treatment strategies.
• To assess the impact of new approaches on patient outcomes, cost, and toxicity.

Main Methods:

• Review of current literature on IFIs in HSCT.
• Evaluation of novel antifungal agents (e.g., voriconazole, caspofungin) for therapy and chemoprophylaxis.
• Assessment of new diagnostic tools, including fungal antigen detection and PCR-based methods.

Main Results:

• Newer antifungal agents demonstrate enhanced potency and broader spectrum activity against yeasts and molds.
• Advanced diagnostic techniques improve the accuracy of preclinical IFIs diagnosis when combined with clinical criteria.
• These advancements hold promise for altering treatment paradigms in IFIs management.

Conclusions:

• Novel antifungal agents and improved diagnostics are crucial for managing IFIs in HSCT recipients.
• A transition towards pre-emptive therapy, guided by enhanced diagnostics, may reduce costs and toxicity.
• Optimizing IFI management is essential for improving survival rates in HSCT patients.